215 related articles for article (PubMed ID: 11522186)
1. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance.
Palmer S; Margot N; Gilbert H; Shaw N; Buckheit R; Miller M
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1167-73. PubMed ID: 11522186
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.
Miller MD; Margot NA; Hertogs K; Larder B; Miller V
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1025-8. PubMed ID: 11562951
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
5. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408.
Miller MD; Margot NA; Lamy PD; Fuller MD; Anton KE; Mulato AS; Cherrington JM
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):450-8. PubMed ID: 11511821
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic susceptibilities to tenofovir in a large panel of clinically derived human immunodeficiency virus type 1 isolates.
Harrigan PR; Miller MD; McKenna P; Brumme ZL; Larder BA
Antimicrob Agents Chemother; 2002 Apr; 46(4):1067-72. PubMed ID: 11897591
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.
Palmer S; Shafer RW; Merigan TC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2046-50. PubMed ID: 10428934
[TBL] [Abstract][Full Text] [Related]
9. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains.
Srinivas RV; Fridland A
Antimicrob Agents Chemother; 1998 Jun; 42(6):1484-7. PubMed ID: 9624498
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.
Mulato AS; Cherrington JM
Antiviral Res; 1997 Nov; 36(2):91-7. PubMed ID: 9443665
[TBL] [Abstract][Full Text] [Related]
12. K65R, TAMs and tenofovir.
Miller MD
AIDS Rev; 2004; 6(1):22-33. PubMed ID: 15168738
[TBL] [Abstract][Full Text] [Related]
13. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors.
Hill SA; Lloyd PA; McDonald S; Wykoff J; Derse D
J Infect Dis; 2003 Aug; 188(3):424-7. PubMed ID: 12870124
[TBL] [Abstract][Full Text] [Related]
15. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.
Margot NA; Isaacson E; McGowan I; Cheng AK; Schooley RT; Miller MD
AIDS; 2002 Jun; 16(9):1227-35. PubMed ID: 12045487
[TBL] [Abstract][Full Text] [Related]
16. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.
Gu Z; Allard B; de Muys JM; Lippens J; Rando RF; Nguyen-Ba N; Ren C; McKenna P; Taylor DL; Bethell RC
Antimicrob Agents Chemother; 2006 Feb; 50(2):625-31. PubMed ID: 16436719
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
Stone C; Ait-Khaled M; Craig C; Griffin P; Tisdale M
Antimicrob Agents Chemother; 2004 Apr; 48(4):1413-5. PubMed ID: 15047556
[TBL] [Abstract][Full Text] [Related]
18. Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates.
Gong YF; Marshall DR; Srinivas RV; Fridland A
Antimicrob Agents Chemother; 1994 Jul; 38(7):1683-7. PubMed ID: 7979311
[TBL] [Abstract][Full Text] [Related]
19. Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Palmer S; Alaeus A; Albert J; Cox S
AIDS Res Hum Retroviruses; 1998 Jan; 14(2):157-62. PubMed ID: 9462926
[TBL] [Abstract][Full Text] [Related]
20. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication.
Naeger LK; Margot NA; Miller MD
Antivir Ther; 2001 Jun; 6(2):115-26. PubMed ID: 11491416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
